

CONTENTS

	Page
CONTENTS	vi
LIST OF TABLES	viii
LIST OF FIGURES	x
LIST OF ABBREVIATIONS AND SYMBOLS	xi
CHAPTER	
1. INTRODUCTION	
1.1 General introduction	1
1.2 Tuberculosis	3
1.3 Stability study	5
1.4 Rifampicin	8
1.5 Isoniazid	10
1.6 Ethambutol	11
1.7 Pyrazinamide	12
2 EXPERIMENTAL	
2.1 Apparatus and instruments	13
2.2 Chemicals	13
2.3 Samples	14
2.4 Analytical method	14
2.5 Samples preparation	16
2.6 Drug quality	16
2.7 Non-isothermal stability	16
2.8 Program validation	17
2.9 Isothermal stability	17
2.10 Statistical data analysis	18
3 RESULTS AND DISCUSSIONS	
3.1 Analytical method	19
3.2 Method validation	21
3.3 Non-isothermal stability study	22
3.4 Program validation	24
3.5 Drug quality	26

CONTENTS (Continued)

	Page
3.6 Isothermal stability study	27
4 CONCLUSIONS	50
REFERENCES	51
VITAE	57

LIST OF TABLES

Table	Page
1. Guideline for tuberculosis treatment	5
2. Results of linearity from 5 replications of antituberculosis drugs	20
3. Results of accuracy and precision	21
4. Kinetic parameters from non-isothermal stability	23
5. Percentage of the amount of anti-tuberculosis drugs before the isothermal stability study	26
6. ANOVA of percentage of rifampicin remaining from isothermal stability	27
7. Pairwise comparisons between temperature to time (months) of rifampicin	28
8. Pairwise comparisons between temperature to relative humidity of rifampicin	29
9. ANOVA of percentage of ethambutol remaining from isothermal stability	30
10. Multiple comparison temperature of ethambutol	31
11. Pairwise comparisons between relative humidity to time (month) of ethambutol	32
12. ANOVA of percentage of pyrazinamide remaining from isothermal stability	33
13. Pairwise comparisons between temperature to time (months) of pyrazinamide	35
14. Pairwise comparisons between temperature to relative humidity of pyrazinamide	36
15. ANOVA of percentage of isoniazid remaining from isothermal stability	37
16. Pairwise comparisons between temperature to relative humidity of isoniazid	39
17. Predicted kinetic parameters of antituberculosis drugs from isothermal stability at 30°C by using Arrhenius equation	41

LIST OF TABLES (Continued)

Table	Page
18. Constants from nonlinear regression (hooke-Jeeves and Quai-newton estimated method) and extrapolated shelf-lives at 30°C	42

LIST OF FIGURES

Figure	Page
1. Chemical structures of rifampicin and its decomposition products	10
2. Chromatogram of rifampicin and indomethacin	19
3. Chromatogram of isoniazid and pyrazinamide	20
4. Reaction of ethambutol and cupric ion in basic medium	20
5. Concentration change in isoniazid pyrazinamide and rifampicin	23
6. Concentration change in ethambutol	23
7. Plot of simulated E_a/R versus E_a/R recovery	25
8. Plot of A simulated versus A recovery	25
9. Plot of T90 simulated versus T90 recovery	26
10. Percentage of rifampicin remaining versus time at nine conditions from isothermal stability	28
11. Percentage of ethambutol remaining versus time at nine conditions from isothermal stability	32
12. Percentage of pyrazinamide remaining versus time at nine conditions from isothermal stability	35
13. Percentage of isoniazid remaining versus time at at nine conditions from isothermal stability	38
14. Correlation of the predicted shelf-lives of antituberculosis drugs (T90%) at 25 and 30°C by the Arrhenius method and the Yoshioka method.	44
15. Compared Arrhenius method and Yoshioka method for predicting percentage of ethambutol remaining after isothermal-stability study at nine conditions	46
16. Compared Arrhenius method and Yoshioka method for predicting percentage of isoniazid remaining after isothermal-stability study at nine conditions	47
17. Compared Arrhenius method and Yoshioka method for predicting percentage of pyrazinamide remaining after isothermal-stability study at nine conditions	48
18. Compared Arrhenius method and Yoshioka method for predicting percentage of rifampicin remaining after isothermal-stability study at nine conditions	49

LIST OF ABBREVIATIONS AND SYMBOLS

ANOVA	Analysis of variance
BCS	Biopharmaceutic Classification System
BP	British Pharmacopoeia
°C	Degree Celsius
E_a	Activation energy
FDC	Fixed dose combination
HPLC	High performance liquid chromatography
mg	Milligram
ml	Milliliter
µg	Microgram
R	Gas constant
R^2	Coefficient of determination
RH	Relative humidity
RSD	Relative standard deviation
SD	Standard deviation
SSE	Sum of square error
USP	the United States Pharmacopoeia
UV	Ultraviolet
w/w	Weight by weight